Journey Medical Corp

Journey Medical Corp has a market capitalization of $135.55 million and a price-to-book ratio of 4.26, indicating a premium valuation relative to its book value. The company holds $24.09 million in cash and equivalents but carries $25.28 million in long-term debt, resulting in a net cash position of -$1.19 million. The current ratio of 1.79 suggests moderate liquidity, with current assets covering current liabilities 1.79 times over.

Profitability metrics are negative, with a return on equity of -35.89% and a return on assets of -12.08%. The company reported a net loss of $11.43 million and an operating loss of $8.17 million in the latest period. Gross profit of $40.93 million on $61.86 million in revenue indicates a gross margin of 66.17%, which is strong but insufficient to offset operating and net losses.

The company operates as a single business segment focused on dermatology pharmaceuticals, with all revenue derived from the United States. There is no geographic diversification, and the company does not disclose revenue by product line or therapeutic area.

Outlook for the current fiscal year shows a projected revenue decline, with no specific percentage provided. The company has not disclosed forward-looking guidance for the next fiscal year. Historical revenue growth is not available due to the company's recent public listing and limited financial history.

Risk factors include a negative net cash position, which could constrain operational flexibility. The company has a low dilution risk, with no recent share issuance or shelf registration activity. Adjustments to valuation metrics have not been applied due to the absence of material dilutive events.

Recent events include the filing of a Form 10-K for the fiscal year ended December 31, 2023, and a Form 10-Q for the quarter ended March 31, 2024. No material developments were disclosed in the most recent earnings call transcript.

Journey Medical Corp (DERM.O) has recorded a series of notable new institutional holdings, marking the first analysis for the ticker with no prior basis for delta computation. The most significant addition involves an investor holding 764,147 shares valued at approximately $5.89 million as of December 31, 2025. This position represents a weight of roughly 0.000085% in the investor's portfolio, signaling early-stage accumulation by external capital. Additional notable additions were detected across multiple reporting periods, further broadening the shareholder base. As of March 31, 2026, one investor held 390,138 shares valued at $1.83 million, while another held 237,288 shares worth $1.11 million. Smaller positions were also established during this period, including holdings of 45,331 shares ($0.21 million), 10,535 shares ($0.05 million), and 11,215 shares ($0.05 million). Earlier activity includes a position of 51,864 shares valued at $0.29 million as of June 30, 2024. These consistent "add" signals across different investors and timeframes suggest growing interest in the company's equity, despite the absence of analyst coverage or index membership. The company currently reports zero officers and zero analysts in its profile, highlighting a lack of traditional market infrastructure surrounding the stock. The significance of these changes lies in the expansion of Journey Medical's top holder count to 15 entities. With no analyst estimates or ESG ratings currently available, these institutional additions provide the primary data points for assessing market sentiment. The accumulation of shares by multiple distinct investors indicates a foundational shift in ownership structure, potentially laying the groundwork for increased liquidity and visibility in the future.